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Background: The purpose of the study is to describe the clinical course and treatment of idiopathic retinitis,
vasculitis, aneurysms and neuroretinitis. The study utilized non-randomized, retrospective and interventional case
series. The eight eyes of six patients were analysed. Testing included wide fluorescein angiography, indocyanine
green angiography and systemic evaluation. Treatment involved observation, panretinal laser photocoagulation
(PRP) for peripheral retinal ischemia, grid laser for macular oedema and focal laser on the macroaneurysms. The
main outcome measures were initial visual acuity (VA), initial stage at diagnosis, clinical course, surgical intervention,
final VA, final stage and complications of disease.
Results: Five out of eight eyes with retinal ischemia in more than two quadrants that were treated with PRP and
grid laser for macular oedema maintained excellent VA and demonstrated no progression of retinal ischemia during
follow-up. The two eyes which exhibited retinal ischemia in less than two quadrants and macular oedema were
treated with grid laser and focal laser on the macroaneurysms, but did not undergo PRP. VA improved by two lines
of the Snellen chart, and there was no progression of retinal ischemia during the 3 and 4 years of follow-up.
One eye with neither retinal ischemia nor macular oedema was not treated, and the clinical picture remained
stable during the follow-up.
Conclusion: Early PRP may be considered in the presence of angiographic evidence of peripheral retinal non-
perfusion. However, treatment could be withheld until the patient develops retinal ischemia in more than two
quadrants.
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Idiopathic retinal vasculitis, arteriolar macroaneurysms
and neuroretinitis (IRVAN) is a rare but well-defined
clinical entity. Patients are usually young, with an
average age of 30 years old at presentation, with female
predominance and no associated systemic illness. The
disorder may present with exudation, which is caused by
the macroaneurysms, and vascular sheathing. The
macroaneurysms of IRVAN may present throughout the
fundus but are more common on the larger retinal
arterioles, typically on the bifurcations. They have the
tendency to leak with lipid deposition which can lead to* Correspondence: alexrouvas@gmail.com
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in any medium, provided the original work is pvisual loss if there is extension towards the macula.
Peripheral capillary non-perfusion is another main
predisposing factor of vision loss and a prominent fea-
ture of the syndrome. It may progress posteriorly and
lead to pre-retinal neovascularization and secondary
vasoproliferative complications [1,2].
Management of IRVAN reveals a variety of treatment
suggestions. The therapeutic regimens advocated include
panretinal laser photocoagulation (PRP), macular grid
photocoagulation, surgery, transcleral cryotherapy, steroids
therapy and administration of monoclonal antibodies such
as ranibizumab and infliximab [2-4].
Samuel et al. conducted the largest cohort study of
IRVAN patients and concluded that PRP should be
considered in the presence of retinal ischemia, irrelevant
to the extent of retinal non-perfusion, in order toan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Staging of the ocular findings in idiopathic
retinal vasculitis, arteriolar macroaneurysms and
neuroretinitis
Stage Ocular findings
1 Macroaneurysms, exudation, neuroretinitis, retinal vasculitis
2 Capillary non-perfusion (angiographic evidence)
3 Posterior segment neovascularization of disc or elsewhere
and/or vitreous haemorrhage
4 Anterior segment neovascularization (rubeosis iridis)
5 Neovascular glaucoma
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and to ensure a good long-term visual outcome [5].
In our study PRP application for each patient was
individualised according to the degree of retinal ische-
mia, and a staging system is proposed to quantify retinal
ischemia (Table 1).
Results
Demographic information, clinical data and the type of
treatment are listed in the Table 2. A total of eight eyes
of six patients were studied retrospectively. Two patients
had bilateral disease (patient numbers 3 and 4). Average
age at the time of diagnosis was 47 years (range, 34 to
80 months). There was female predominance by 5:1. All
patients were Caucasian. The average length of follow-
up was 25.6 months (range, 19 to 48 months). Two eyes
had retinal ischemia in less than two quadrants (patient
numbers 5 and 6) and five eyes in more than two
quadrants (cases 1, 3 and 4). All reached stage 2 of the
disease at the last follow-up, apart from one eye which
was classified as stage 1 at the time of diagnosis (patient
number 1). The clinical course of each eye after the initi-
ation of treatment was evaluated with respect to the final
VA and the stage of ischemic retinopathy at the initi-
ation of treatment.
Five out of eight eyes with ischemia in more than two
quadrants were treated with PRP (cases 1, 3, 4, 5 and 6),
and one of these eyes also underwent grid laser (case 1).











1 36/F 1 Right 9/10 9/10 275 228
2 47/F 2 Left 10/10 10/10 236 221
3 34/F 3 Right 8/10 9/10 218 228
4 Left 08/10 09/10 220 225
4 38/M 5 Right 10/10 10/10 230 227
6 Left 10/10 10/10 221 218
5 80/F 7 Right 3/10 5/10 285 225
6 48/F 8 Left 7/10 9/10 267 218
BCVA best corrected visual acuity; CFT central foveal thickness; PRP panretinal photoperiod and demonstrated no progression of the retinal
ischemia. The two out of eight eyes at stage 2 (cases 7
and 8), which exhibited retinal ischemia in less than
two quadrants, were treated only with grid laser on
the macular area of leakage and focal laser on the
macroaneurysms (Figures 1F, G and 2E). At the end of
follow-up period, the VA improved by two lines of the
Snellen chart, and there was no progression of retinal is-
chemia during the 3 and 4 years of follow-up respect-
ively. The last one eye of stage 1 was not treated,
and the clinical picture remained stable during the 19
months of follow-up. Among the three eyes with macu-
lar oedema that were treated with grid laser (cases 1, 7,
8), the mean central foveal thickness (CFT) measured by
optical coherence tomography (OCT) at initial visit was
276 μm (range, 267 to 285 μm) and at final visit was 224
μm (range, 218 to 228 μm) (Table 2). Written informed
consents (in Greek) were obtained from the patient for
publication of this article and accompanying images.Discussion
There is little firm information on the natural history
and visual outcome of the disease in literature. All of the
reported cases have limitations, such as small sample
size, adopting therapeutic regimens that have limited
scientific validity, narrow period of follow-up and per-
sonal biases. Several features have been reported about
IRVAN, including an association with fungal sinusitis,
initial presentation as optic disc oedema with elevated
intracranial hypertension and a rapid change in the
dynamics of the aneurysms [6-8].
Over the years, many therapeutic regimens have been
evaluated. The main treatments can be divided into
three categories: (1) medical, (2) surgical and (3) photo-
coagulation which includes PRP, focal laser on leaking
macroaneurysms and grid laser photocoagulation for
macular oedema.
The presence of the anterior chamber and vitreous











2 2 Yes Yes No 24
1 1 No No No 7
2 2 Yes No No 24
2 2 Yes No No 24
1 2 Yes No No 18
1 2 Yes No No 18
2 2 No Yes Yes 24
2 2 No Yes Yes 36
coagulation; F female; M male.
Figure 1 Arteriovenous phase fluorescein angiogram of retinal arterioles. (A) Arteriovenous phase fluorescein angiogram (FA) showing
multiple aneurysmal dilatations along the upper and lower temporal retinal arterioles (white arrow heads) as well as the abrupt obstruction of the
lower temporal arterial branch (black arrow). (B) FA at 2.5 min demonstrating multiple aneurysms along bifurcations of retinal arcades (black
arrow heads) and vasculitis along the lower temporal arterial arcade (white arrows). (C, D) Wide FA displaying retinal ischemia in less than two
quadrants (area between the white arrows) and a hot disc. (E) Indocyanine green angiogram (ICG) illustrating multiple aneurysmal dilatations
along the upper and lower temporal retinal arterioles and the abrupt obstruction of the lower temporal arterial branch (black arrow). (F, G) Late
phase FA and mid-phase ICG 12 months post-treatment demonstrating the area of grid laser photocoagulation (white arrows), and the
obstruction of the arterial branch peripheral to the focal laser (black arrow) with cessation of leakage. (H) Wide FA 36 months post-treatment
showing no progression of retinal ischemia to more than two quadrants. (I) OCT pre-treatment showing intraretinal (white arrow) and subretinal
fluid (white arrowhead). (K) OCT post-treatment demonstrating resolution of macular oedema.
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Figure 2 Infrared fundus photograph of left eye. (A) Infrared fundus photograph of left eye showing blood (white arrow) and hard exudates
(black arrow). (B) Arteriovenous phase FA showing macroaneurysms along bifurcations of retinal arcades (white arrow) as well as vasculitis of
retinal arterioles (black arrow). (C) Late phase FA demonstrating leakage from the macroaneurysms and telangiectatic retinal net (white arrow).
(D) Infrared fundus photograph 12 months post-treatment showing no hard exudates or blood. (E) Arteriovenous phase FA 12 months post-
treatment demonstrating the area of grid laser photocoagulation (white arrows) as well as the focal laser at the macroaneurysm (black arrow).
(F) Late phase FA 12 months post-treatment showing no dye leakage. (G) Wide FA 12 months post-treatment displaying ischemia in less than
two quadrants of the retina. (H) Magnified triangular area of retinal ischemia of the previous picture on wide FA with aneurismal dilatations along
retinal bifurcations (white arrows) and vasculitis (black arrow). (I) Wide FA 48 months post-treatment showing no progression of ischemia.
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result of a migratory inflammatory process involving the
alternate segments along the vascular tree [9]. However,
therapeutic response to steroids is absent or minimal
[1,2,5,8,10]. In the quest of better alternatives to steroids,
antitumor necrosis factor agent therapy has been
appraised with promising results [4].
Vitrectomy has been used in the presence of vitreous
haemorrhage and in conjunction to PRP in an attemptto improve visual outcome [5]. Recently, a case report
has been published regarding the use of intravitreal
ranibizumab treatment combined with PRP and vitrec-
tomy [3].
PRP has been suggested as the treatment of choice for
IRVAN in the presence of widespread retinal ischemia so
as to prevent the development of ocular neovascularization
and vitreous haemorrhage [5]. The rationale for this
therapeutic approach was based on the results of the
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(CRVO) Study, which recommended argon laser PRP in
high risk proliferative diabetic retinopathy and CRVO with
iris neovascularisation respectively [11,12]. According
to both studies, the presence of retinal or iris
neovascularisation was a prerequisite for the initiation
of PRP. However, Samuel et al. state that visual prog-
nosis may depend on the early initiation of treatment
with PRP for extensive ischemic retinal disease, even
without the presence of neovascularization [5].
The extent of retinal non-perfusion though was not
quantified.
In our case series, all eyes that were treated with PRP,
irrelevant to the extent of retinal non-perfusion,
maintained excellent VA and demonstrated no progres-
sion of retinal ischemia. Two eyes at stage 2, which
exhibited retinal ischemia in less than two quadrants,
were treated only with grid laser for macular oedema
and focal laser on the macroaneurysms. VA improved by
two lines of the Snellen chart, and there was no progres-
sion of retinal ischemia during the 3 and 4 years of
follow-up period of these eyes (Figures 1H and 2I). One
eye of stage 1 was not treated and the clinical picture
remained stable.
Exudative maculopathy was responsible for the initial
decrease in vision in the seven eyes of the review by
Samuel et al. and in the five eyes of our patients. After
application of grid/focal photocoagulation, two thirds of
the eyes of the review maintained a VA within one line
of the initial VA and all of our patients improved their
VA by one or two Snellen lines. Direct photocoagulation
to leaking macroaneurysms has been opposed due to the
occlusion of the blood vessel originating at the site of
the vessel burn [4,13]. However, laser was applied on the
leaking macroaneurysms temporal to the fovea. Subse-
quent obstruction of the arterial branch in one eye did
not affect VA and successfully prevented the leaking of
the dye in FA (Figure 1F, G).
Conclusions
Our results along with the authors suggest that the ap-
plication of PRP may be useful in the treatment of
patients with IRVAN. However, as the root of the disease
is unknown, treatment does not eliminate the cause
but aims to reduce or eliminate macular oedema,
prevent long-term macular changes and the destructive
consequences of retinal ischemia. The precise time to
initiate treatment is controversial; as in opposition to
other ischemic retinopathies, there have been no
randomized prospective clinical trials.
In our patients, deferral of PRP when peripheral ische-
mia is present in less than two quadrants of the retina
did not appear to result in progression of the ischemia
in a follow-up period of 3 and 4 years for the two of thesix of our patients. Therefore, treatment could be with-
held until the patient develops retinal ischemia in more
than two quadrants. For these circumstances wide fluor-
escein angiography (WFA) can be a useful diagnostic
tool. Randomized studies with higher numbers of
patients and long follow-up periods are required to dem-
onstrate the benefits and efficacy of PRP in the manage-
ment of IRVAN as well as its role in preventing
recurrences.
Methods
We retrospectively evaluated the medical records, fun-
dus photographs and investigative studies of six patients
who presented to our clinic with IRVAN within the last
5 years. The diagnostic studies included WFA and
ICG with Heidelberg retinal angiography-2 (HRA-2,
Heidelberg Engineering, Heidelberg, Germany) and
OCT (Carl Zeiss, Meditec, Jena, Germany). Tests were
initially performed at 3-month intervals for 1 year and at
6-month intervals for the following years, in order to
appraise the clinical course of the disease and the effi-
cacy of each treatment regimen. In view of the above
tests, we also adopted a proposed classification scheme
for staging retinal ischemia in IRVAN as proposed by
Samuel et al. (Table 1). This classification has been
proposed for other diseases such as central retinal vein
occlusion and diabetic retinopathy. Additionally though,
we implemented an advanced classification for stage
2 and onwards, where capillary non-perfusion was
evaluated separately for each of four quadrants of the
retina, based on WFA findings with the Straurenghi 230
scanning laser ophthalmoscope retina lens (Ocular
Instruments, Glenfield, Auckland).
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